NCT03943251View on ClinicalTrials.gov

The Study of a Selective Serotonin Partial Agonist and Reuptake Inhibitors, HEC113995PA•H2O,in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

July 4, 2019

Primary Completion Date

December 11, 2019

Study Completion Date

December 11, 2019

Conditions
Healthy
Interventions
DRUG

HEC113995PA•H2O tablet

2.5-、5-、10-、20-、40-、60-、80mg HEC113995PA•H2O tablet in day1.

DRUG

Placebo tablet

2.5-、5-、10-、20-、40-、60-、80mg Placebo tablet in day1.

Trial Locations (1)

Unknown

The Shanghai xuhui district central hospital, Shanghai

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT03943251 - The Study of a Selective Serotonin Partial Agonist and Reuptake Inhibitors, HEC113995PA•H2O,in Healthy Subjects | Biotech Hunter | Biotech Hunter